Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4957148 | 1.00 | NR1H4 (0.46) | NR1H4SCN10ACHRM2CHRM5CHRM3 | |
| Trifluoroacetic Acid SCHEMBL4958295 | 0.88 | NR1H4 (0.39) | NR1H4SCN10A | |
| Trifluoroacetic Acid SCHEMBL4958292 | 0.88 | NR1H4 (0.39) | NR1H4SCN10A | |
| SCHEMBL951881 | 0.78 | NR1H4 (0.49) | NR1H4CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL15934142 | 0.78 | NR1H4 (0.49) | NR1H4CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL174089 | 0.78 | NR1H4 (0.49) | NR1H4CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL15931973 | 0.74 | NR1H4 (0.49) | NR1H4CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL19478978 | 0.74 | NR1H4 (0.49) | NR1H4CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL15932007 | 0.74 | NR1H4 (0.49) | NR1H4CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL6371414 | 0.74 | NPC1 (0.45) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015146-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-01-17 | — | — | US | disclosed |
| EP-1786806-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2005121131-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015146-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP3 | NR1H4 1322/4885SCN10A 803/4885CHRM2 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.